|
23 Jan 2019 |
Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine
|
|
23 Jan 2019 |
Immunochina Raises $20.4 Million USD in Series C Financing
|
|
23 Jan 2019 |
Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
|
|
21 Jan 2019 |
Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients
|
|
19 Jan 2019 |
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
|
|
18 Jan 2019 |
OliX Announces Clinical Candidate Nomination for the Treatment of Geographic Atrophy
|
|
11 Jan 2019 |
Inovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward with First-in-Human Trial
|
|
10 Jan 2019 |
NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
|
|
09 Jan 2019 |
Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives
|
|
09 Jan 2019 |
Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)
|
|
07 Jan 2019 |
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
|
|
07 Jan 2019 |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
|
|
07 Jan 2019 |
Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
|
|
07 Jan 2019 |
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke
|
|
07 Jan 2019 |
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
|
|
07 Jan 2019 |
Homology Medicines Advances First Gene Editing Development Candidate into IND-Enabling Studies for Pediatric Patients with Phenylketonuria
|
|
07 Jan 2019 |
Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019
|
|
05 Jan 2019 |
Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
|
|
05 Jan 2019 |
Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors
|
|
03 Jan 2019 |
Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
|
|
03 Jan 2019 |
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
|
|
03 Jan 2019 |
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
|
|
03 Jan 2019 |
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
|
|
22 Dec 2018 |
Benitec Provides Update on BB-401 Cancer Treatment Program
|
|
22 Dec 2018 |
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)
|
